Consistent with these results, previous preclinical studies demonstrated that knockdown of PKM2 can inhibit gastric cancer cell proliferation and G1‐S phase transition, attenuate gastric cancer cell migration, and promote autophagy, which may depend on mediating the PI3K/Akt signaling.30 These findings suggest that PKM2 might serve as a novel prognostic biomarker and target that would allow for a novel treatment strategy for metastatic RCC in clinical settings. The gene discussed is AKT1; the disease is gastric cancer.